ArticlePloS one2025
Predicting severe renal dysfunction in alcohol-associated cirrhosis: Comparative performance of liver function scores and machine learning models.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on "Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure".Hepatology international · 2026Article
- From digital assistants to clinical partners: revolutionizing pediatric urology through large language model-powered decision support and patient education.World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal dysfunction is a frequent and clinically relevant complication of cirrhosis, yet chronic kidney disease (CKD) often remains underrecognized, particularly in non-acute settings. Early identification of at-risk patients is essential to guide timely interventions. Although MELD, Child-Pugh Score (CPS), APRI, and FIB-4 are widely used to assess hepatic disease severity, their predictive value for advanced renal dysfunction is uncertain.
methodsIn this retrospective cohort study (2014-2021, Klinikum Stuttgart), we evaluated the ability of MELD, CPS, APRI, and FIB-4 to predict severe renal dysfunction (chronic kidney disease [CKD] stage ≥ 3, according to Kidney Disease: Improving Global Outcomes [KDIGO] classification) in patients with alcoholic cirrhosis. Logistic and linear regression analyses were performed. In addition, machine learning (ML) models were trained to identify non-renal predictors of CKD stage ≥ 3.
resultsAmong 131 patients (mean age 62.8 ± 11.3 years; 71% male), 33% met criteria for KDIGO stage ≥ 3. MELD was significantly associated with advanced CKD (OR = 1.379, p < 0.001), with prevalence increasing from 17% (MELD ≤ 9) to 80% (MELD ≥ 20). CPS showed an inverse association (p = 0.002), while APRI and FIB-4 were not predictive. The optimized Random Forest model, refined through ROSE oversampling and feature selection, achieved an AUC of 0.757, with 76% accuracy, 82% sensitivity (KDIGO < 3), and 63% specificity (KDIGO ≥ 3).
conclusionMELD was the most reliable conventional score for identifying advanced renal dysfunction in alcoholic cirrhosis. ML-based models incorporating routinely available clinical parameters further improved predictive performance and may support risk stratification in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.